Skip to main content
main-content
Oncology

PROfound paves the way for precision medicine in mCRPC

DNA mutation

Treatment with the PARP inhibitor olaparib improves the outcomes of men with metastatic castration-resistant prostate cancer harboring deleterious mutations in homologous recombination repair genes, show trial results.

Respiratory

Monocyte counts could predict IPF outcome

Monocyte

Elevated monocyte counts are associated with poor outcomes among patients with idiopathic pulmonary fibrosis, suggest study findings published in The Lancet Respiratory Medicine.

Rheumatology

Differential DNA methylation may help identify likely methotrexate responders

DNA

Changes in DNA methylation following initiation of methotrexate appear to correlate with response to the drug in patients with rheumatoid arthritis, study findings indicate.

Headlines from across medwireNews

17-10-2019 | Rheumatology | News | Article

Treatment switching associated with VTE risk in RA

People with rheumatoid arthritis who switch between different biologic or targeted synthetic DMARDs have a higher risk for venous thromboembolism than those who remain on the same treatment, researchers report.

17-10-2019 | Oncology | News | Article

Neoadjuvant nivolumab tested for metastatic RCC

Results from the ADAPTeR study suggest that giving nivolumab before and after cytoreductive nephrectomy or metastatic biopsy may be a feasible strategy for patients with treatment-naïve metastatic clear cell renal cell carcinoma.

17-10-2019 | Oncology | News | Article

Durvalumab NSCLC clinical benefit achieved without negative impact on PROs

Analysis of data from the PACIFIC trial shows that levels of key patient-reported outcomes such as cough, fatigue, and quality of life, do not differ significantly between patients with advanced non-small-cell lung cancer treated with durvalumab after chemoradiotherapy and those who received placebo.

16-10-2019 | Diabetes | News | Article

iDCL trial shows sustained time in range improvement with hybrid closed-loop delivery

People with type 1 diabetes using the Tandem Control-IQ hybrid closed-loop insulin delivery system spent significantly more time within their target blood glucose range than people using a sensor-augmented insulin pump during 6 months of use in the iDCL trial.

16-10-2019 | Diabetes | News | Article

Islet transplantation benefits endure over 10 years

Three-quarters of people who undergo islet transplantation for type 1 diabetes have sustained graft survival with associated improvements in glucose control, insulin requirements, and hypoglycemia incidence 10 years later, research shows.

16-10-2019 | Oncology | News | Article

​​​​​​​Enfortumab vedotin–pembrolizumab duo has potential in urothelial carcinoma

Combining enfortumab vedotin with pembrolizumab could be a promising option for the first-line treatment of cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer, indicates the EV-103 trial.

medwireNews is an established provider of authoritative, timely and independent medical news. We value your feedback and encourage you to contact us to make medwireNews.com your preferred medical news resource.

Meet the team

Image Credits